Jun 18, 2020
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 22, 2020
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
May 19, 2020
Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454
Apr 27, 2020
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
Apr 14, 2020
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
Apr 01, 2020
Global Immune Checkpoint Inhibitors Market Outlook 2022
Mar 16, 2020
2020 Market Spotlight: Small-Cell Lung Cancer (SCLC)
Feb 25, 2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
Feb 24, 2020
Top 10 Cancer Drugs Market Study, 2018-2026 - Keytruda Anticipated to Grow at the Highest Rate
Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Feb 15, 2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
Feb 07, 2020
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-oncology Symposium
Feb 03, 2020
$100+ Billion Immuno-Oncology Market Insights, 2022 - Opdivo and Keytruda Presents Significant Growth Opportunity
Jan 15, 2020
John Theurer Cancer Center Participating in Early-Phase Study of Immunotherapy-Boosting Treatment
Nov 21, 2019
Cancer Drugs and New Therapies for Dangerous Brain Tumors Advancinghl2Financialnewsmedia.com News Commentary
Nov 14, 2019
Leap Therapeutics Reports Third Quarter 2019 Financial Results
Nov 05, 2019
PathAI and Bristol Myers-Squibb to Showcase Results From First AI-Powered Analysis of PD-L1 Expression Across Three Phase 3 Trials at SITC 2019
Oct 23, 2019
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting